Drug intelligence / Profile preview

Biogaze

Development stage: Unknown
Lead developer: Novum Pharma
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Topical

Overview

Biogaze is an over-the-counter (OTC) consumer health product line developed and marketed by Novum Pharma for wound care. Available in multiple formats including hydrogels, sprays, and medicated gauzes, it is indicated for the treatment of minor skin injuries such as superficial burns, cuts, and abrasions. The product line is designed to promote healing by protecting the wound site, maintaining a moist environment, and, in specific formulations like the spray, providing antiseptic and local analgesic effects to prevent infection and alleviate pain. Biogaze is widely distributed internationally as a first-aid essential.

Brand names: Biogaze

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Biogaze.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biogaze.

Explore the full profile